Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 52,87 € (+180,18 %). Medianen er 58,80 € (+211,61 %).

Køb
  32
Behold
  6
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Uniqure rises after William Blair 'outperform' and progress on AMT-130

    Uniqure shares gained about 2.4% in premarket trading after William Blair initiated coverage with an “Outperform” rating. Analysts are broadly optimistic (11 buy, 1 hold), and agreement with the FDA on an accelerated approval pathway for AMT-130 has boosted investor sentiment. Uniqure also benefited from a solid cash position and an amended credit facility with Hercules Capital; the recent roughly 175% rally from the 52-week low is seen as company-specific. » Mere på de.investing.com


  • uniQure receives FDA confirmation for accelerated BLA pathway for AMT-130 and reports sales increase

    uniQure said the FDA confirmed in writing after a Type B meeting that a BLA filing for Huntington’s therapy AMT-130 is appropriate under an accelerated pathway based on existing clinical data. The company beat revenue consensus in Q2 with $5.84m, but reported a higher net loss per share due to increased selling, general and administrative expenses. uniQure plans to file regulatory applications in the US and the UK in Q3 2026, strengthened its balance sheet with a $259m capital raise and extended its cash runway to 2030. The announcements pushed the stock about 6.3% higher in premarket trading. » Mere på de.investing.com


  • UniQure beats revenue estimate and secures $259 million financing through 2030

    UniQure reported Q2 revenue of $5.80 million, exceeding the consensus expectation of $5.47 million, while net loss widened due to higher selling, general and administrative and non‑operating expenses. The revenue increase was driven by higher license income; rising personnel and contractor costs reflect preparations for potential product launches. Through a follow‑on placement, UniQure raised $259 million and says this secures liquidity through 2030; regulatory filings for AMT‑130 are planned for Q3 2026 and topline four‑year data are expected in September 2026. » Mere på de.investing.com


  • uniQure presents mixed Phase I/IIa data on epilepsy gene therapy AMT‑260

    In the low‑dose cohort (1x10^12 gc/mL) of the Phase I/IIa study, three of six patients showed a 79–100% reduction in disabling seizures in months 4–6; the other three patients had changes of −33% to +36% versus baseline. No serious adverse events have been reported to date; adverse events were mild to moderate, headaches were most common, and no immunosuppression was required. Recruitment of a higher‑dose cohort (3x10^12 gc/mL) is ongoing, with completion expected mid‑2026 and updated study data planned for H1 2027. The study announcement drove the share price up 67.9% to 46.29 USD and lifted market capitalization to 2.92 billion USD; an analysis by InvestingPro currently rates the stock as overvalued. » Mere på de.investing.com


  • UniQure to seek FDA approval for Huntington's gene therapy after agency reverses stance

    UniQure plans to submit an FDA application in Q3 for its experimental gene therapy for Huntington's disease after a recent meeting indicated a three-year analysis from a Phase 1/2 study could support accelerated approval. The FDA previously questioned the sufficiency of UniQure's data and had asked for a placebo-controlled trial, but now agrees the company can use external control data and wants to align on a post-approval confirmatory study comparing the treatment to standard of care. UniQure expects to finalize the confirmatory trial design before submitting its application. » Mere på cnbc.com

I 2023 har uniQure allerede udloddet 0,95 € i udbytte. Den seneste udlodning fandt sted i oktober 2023.

Virksomhedstal

I det seneste kvartal havde uniQure en omsætning på 4,59 mio. € og et nettoresultat på -54,05 mio. €
(EUR) september 2026
YoY
Omsætning 4,59 mio. 45,46 %
Bruttofortjeneste 4,38 mio. 55,58 %
Nettoresultat -54,05 mio. 21,24 %
EBITDA -35,77 mio. 18,57 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
1,3 mia. €
Antal aktier
70,14 mio.
Højeste/laveste i 52 uger
47,15 € - 7,96 €
Udbytte Nej
Beta
0,94
P/E (PE Ratio)
-5,73
PEG (PEG Ratio)
-0,40
K/I (PB Ratio)
4,82
P/S (PS Ratio)
70,60

Virksomhedsprofil

uniQure N.V. er et genterapiselskab, der udvikler behandlinger til patienter, der lider af genetiske og andre alvorlige sygdomme. Selskabets førende program er Etranacogene dezaparvovec (AMT-061), som er i det fase III-baserede HOPE-B-nøgleforsøg til behandling af hæmofili B. Selskabet udvikler også AMT-130, en genterapi, der er i et fase I/II-klinisk studie til behandling af Huntingtons sygdom; AMT-060, som er i et fase I/II-klinisk forsøg til behandling af hæmofili B; AMT-210, en produktkandidat til behandling af Parkinsons sygdom; AMT-260 til temporallobeepilepsi; AMT-240, en prækliniske produktkandidat til behandling af autosomal dominant Alzheimers sygdom; og AMT-161 til behandling af amyotrofisk lateral sklerose. uniQure N.V. blev grundlagt i 1998 og har hovedkontor i Amsterdam, Holland.

Navn
uniQure
CEO
Matthew C. Kapusta
Hjemsted Amsterdam, nh
Nederlandene
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
05.02.2014
Medarbejdere 221

Tickersymboler

Børs Symbol
NASDAQ
QURE
London Stock Exchange
0EE0.L
Frankfurt
UQ1.F
London
0EE0.L
SIX
UQ1.SW
🍪

Parqet  bruger cookies. Læs mere